Diversified Trust Co Buys 1,056 Shares of AstraZeneca PLC $AZN

Diversified Trust Co boosted its stake in AstraZeneca PLC (NASDAQ:AZN) by 17.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,125 shares of the company’s stock after acquiring an additional 1,056 shares during the quarter. Diversified Trust Co’s holdings in AstraZeneca were worth $498,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Dynamic Advisor Solutions LLC lifted its position in AstraZeneca by 58.4% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 13,055 shares of the company’s stock worth $960,000 after buying an additional 4,811 shares in the last quarter. SCS Capital Management LLC bought a new stake in AstraZeneca during the 1st quarter worth about $3,066,000. Farther Finance Advisors LLC lifted its position in AstraZeneca by 13.1% during the 1st quarter. Farther Finance Advisors LLC now owns 6,083 shares of the company’s stock worth $442,000 after buying an additional 706 shares in the last quarter. Community Trust & Investment Co. lifted its position in AstraZeneca by 21.2% during the 2nd quarter. Community Trust & Investment Co. now owns 226,161 shares of the company’s stock worth $15,804,000 after buying an additional 39,488 shares in the last quarter. Finally, Strs Ohio bought a new stake in AstraZeneca during the 1st quarter worth about $26,828,000. 20.35% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Berenberg Bank set a $97.00 price target on shares of AstraZeneca in a research report on Wednesday, July 9th. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, AstraZeneca currently has a consensus rating of “Moderate Buy” and an average target price of $86.00.

AstraZeneca Stock Performance

NASDAQ AZN opened at $75.97 on Wednesday. The firm has a market capitalization of $235.61 billion, a price-to-earnings ratio of 28.56, a P/E/G ratio of 1.42 and a beta of 0.37. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.55. The firm’s 50 day simple moving average is $76.84 and its 200 day simple moving average is $72.96. AstraZeneca PLC has a 1 year low of $61.24 and a 1 year high of $82.41.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $1.09 EPS for the quarter, meeting the consensus estimate of $1.09. The business had revenue of $14.46 billion during the quarter, compared to the consensus estimate of $14.08 billion. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The firm’s revenue was up 16.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.24 EPS. As a group, research analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

AstraZeneca Cuts Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Monday, September 8th. Investors of record on Friday, August 8th were paid a $0.505 dividend. The ex-dividend date of this dividend was Friday, August 8th. This represents a yield of 200.0%. AstraZeneca’s dividend payout ratio is presently 37.97%.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.